Astrocytic and neuronal biochemical markers in the sera of subjects with diabetes mellitus.
To determine if clinical diabetes is associated with disruption of the blood-brain barrier (BBB) and/or brain injury, enzyme-linked immunoassays and Western blots were used to measure serum levels of S100B, NSE and their auto-antibodies in type 1 and type 2 diabetic subjects. Serum S100B concentrations in type 2 diabetic subjects, but not in type 1 diabetic subjects, were significantly lower than those found in healthy controls. There were no significant differences in serum NSE levels of either type 1 or type 2 diabetics compared to healthy controls. However, there was a significant increase in antibodies to NSE in both type 1 and type 2 diabetic subjects compared to controls, whereas diabetics and controls had equally very low levels of anti S100B auto-antibodies. These studies suggest that diabetes in humans may be associated with alterations in the BBB integrity that allow the emergence of antibodies against neuronal antigens.